142 related articles for article (PubMed ID: 19850993)
21. Erratum to: Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up.
Kiluk JV; Ly QP; Santillan AA; Meade T; Ramos D; Reintgen DS; Dessureault S; Davis M; Shamehdi C; Cox CE
Ann Surg Oncol; 2010 Feb; 17(2):552-7. PubMed ID: 19957043
[TBL] [Abstract][Full Text] [Related]
22. Sentinel lymph node dissection provides axillary control equal to complete axillary node dissection in breast cancer patients with lobular histology and a negative sentinel node.
Khakpour N; Hunt KK; Kuerer HM; Yi M; Meric-Bernstam F; Ross MI; Lucci A
Am J Surg; 2005 Oct; 190(4):598-601. PubMed ID: 16164930
[TBL] [Abstract][Full Text] [Related]
23. Breast conservation therapy for invasive lobular carcinoma: the impact of lobular carcinoma in situ in the surgical specimen on local recurrence and axillary node status.
Stolier AJ; Barre G; Bolton JS; Fuhrman GM; Looney S
Am Surg; 2004 Sep; 70(9):818-21. PubMed ID: 15481302
[TBL] [Abstract][Full Text] [Related]
24. Surgical treatment of early breast cancer in day surgery.
Marrazzo A; Taormina P; David M; Riili I; Lo Gerfo D; Casà L; Noto A; Mercadante S
Chir Ital; 2007; 59(5):687-91. PubMed ID: 18019641
[TBL] [Abstract][Full Text] [Related]
25. Margin status and the risk of local recurrence after breast-conserving treatment of lobular breast cancer.
van den Broek N; van der Sangen MJ; van de Poll-Franse LV; van Beek MW; Nieuwenhuijzen GA; Voogd AC
Breast Cancer Res Treat; 2007 Sep; 105(1):63-8. PubMed ID: 17115109
[TBL] [Abstract][Full Text] [Related]
26. Sentinel lymph node biopsy in multicentric breast cancer: five-year results in a large series from a single institution.
Gentilini O; Veronesi P; Botteri E; Soggiu F; Trifirò G; Lissidini G; Galimberti V; Musmeci S; Raviele PR; Toesca A; Ratini S; Del Castillo A; Colleoni M; Talakhadze N; Rotmensz N; Viale G; Veronesi U; Luini A
Ann Surg Oncol; 2011 Oct; 18(10):2879-84. PubMed ID: 21479691
[TBL] [Abstract][Full Text] [Related]
27. Role for intraoperative margin assessment in patients undergoing breast-conserving surgery.
Cabioglu N; Hunt KK; Sahin AA; Kuerer HM; Babiera GV; Singletary SE; Whitman GJ; Ross MI; Ames FC; Feig BW; Buchholz TA; Meric-Bernstam F
Ann Surg Oncol; 2007 Apr; 14(4):1458-71. PubMed ID: 17260108
[TBL] [Abstract][Full Text] [Related]
28. [The role of sentinel lymph node biopsy in breast cancer non-invading-duct].
Török K; Péley G; Mátrai Z; Bidlek M; Szabó E; Sinkovics I; Polgár C; Farkas E; Orosz Z; Köves I
Magy Seb; 2006 Jun; 59(3):173-8. PubMed ID: 16937792
[TBL] [Abstract][Full Text] [Related]
29. Can magnetic resonance imaging be used to select patients for sentinel lymph node biopsy in prophylactic mastectomy?
McLaughlin SA; Stempel M; Morris EA; Liberman L; King TA
Cancer; 2008 Mar; 112(6):1214-21. PubMed ID: 18257089
[TBL] [Abstract][Full Text] [Related]
30. Lobular carcinoma in situ of the breast.
Goldschmidt RA; Victor TA
Semin Surg Oncol; 1996; 12(5):314-20. PubMed ID: 8873318
[TBL] [Abstract][Full Text] [Related]
31. Breast magnetic resonance imaging for preoperative locoregional staging.
Hollingsworth AB; Stough RG; O'Dell CA; Brekke CE
Am J Surg; 2008 Sep; 196(3):389-97. PubMed ID: 18436185
[TBL] [Abstract][Full Text] [Related]
32. Axillary regional recurrence after sentinel lymph node biopsy for breast cancer.
Rosing DK; Dauphine CE; Vargas MP; Gonzalez K; Burla M; Kaufmann P; Vargas HI
Am Surg; 2006 Oct; 72(10):939-42. PubMed ID: 17058740
[TBL] [Abstract][Full Text] [Related]
33. High intersystem variability for the prediction of additional axillary non-sentinel lymph node involvement in individual patients with sentinel node-positive breast cancer.
van den Hoven I; Kuijt GP; Voogd AC; Roumen RM
Ann Surg Oncol; 2012 Jun; 19(6):1841-9. PubMed ID: 22207045
[TBL] [Abstract][Full Text] [Related]
34. Mastectomy and concomitant sentinel lymph node biopsy for invasive breast cancer.
Sabel MS; Degnim A; Wilkins EG; Diehl KM; Cimmino VM; Chang AE; Newman LA
Am J Surg; 2004 Jun; 187(6):673-8. PubMed ID: 15191855
[TBL] [Abstract][Full Text] [Related]
35. Lobular carcinoma in situ on core biopsy-what is the clinical significance?
O'Driscoll D; Britton P; Bobrow L; Wishart GC; Sinnatamby R; Warren R
Clin Radiol; 2001 Mar; 56(3):216-20. PubMed ID: 11247699
[TBL] [Abstract][Full Text] [Related]
36. The Yale University experience of early-stage invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) treated with breast conservation treatment (BCT): analysis of clinical-pathologic features, long-term outcomes, and molecular expression of COX-2, Bcl-2, and p53 as a function of histology.
Moran MS; Yang Q; Haffty BG
Breast J; 2009; 15(6):571-8. PubMed ID: 19995377
[TBL] [Abstract][Full Text] [Related]
37. Lobular and non-lobular breast cancers differ regarding axillary lymph node metastasis: a cross-sectional study on 4,292 consecutive patients.
Vandorpe T; Smeets A; Van Calster B; Van Hoorde K; Leunen K; Amant F; Moerman P; Deraedt K; Brouckaert O; Van Huffel S; Wildiers H; Christiaens MR; Neven P
Breast Cancer Res Treat; 2011 Jul; 128(2):429-35. PubMed ID: 21562708
[TBL] [Abstract][Full Text] [Related]
38. Validation of axillary sentinel lymph node detection in the staging of early lobular invasive breast carcinoma: a prospective study.
Classe JM; Loussouarn D; Campion L; Fiche M; Curtet C; Dravet F; Pioud R; Rousseau C; Resche I; Sagan C
Cancer; 2004 Mar; 100(5):935-41. PubMed ID: 14983488
[TBL] [Abstract][Full Text] [Related]
39. [Breast-conserving surgery in breast cancer].
Ruggiero R; Procaccini E; Freda F; Iovino F; Irlandese E; Gili S; Lo Schiavo F
G Chir; 2005; 26(11-12):449-52. PubMed ID: 16472427
[TBL] [Abstract][Full Text] [Related]
40. Axillary lymphectomy in breast cancer.
Barillari P; Leuzzi R; D'Angelo F; Bassiri-Gharb A; Naticchioni E
Minerva Chir; 2002 Apr; 57(2):129-33. PubMed ID: 11941288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
